$Merck & Co (MRK.US)$ US pharmaceutical company MSD released...
$Merck & Co(MRK.US$
US pharmaceutical company MSD released the latest research data on its COVID-19 oral medication, indicating that the efficacy of the drug in reducing the risk of hospitalization or death for patients is only 30%. MSD's latest data is far less effective than the 50% effectiveness announced in October. The company released this data before the US Food and Drug Administration published an analysis report on drug safety. When the US Food and Drug Administration published a preliminary analysis later, it was stated that MSD's oral medication has proven effective in treating COVID-19. However, experts believe that pregnant women are not suitable to take this medication. Experts from the authorities will meet next week to discuss whether to recommend approval for emergency use of the drug.
US pharmaceutical company MSD released the latest research data on its COVID-19 oral medication, indicating that the efficacy of the drug in reducing the risk of hospitalization or death for patients is only 30%. MSD's latest data is far less effective than the 50% effectiveness announced in October. The company released this data before the US Food and Drug Administration published an analysis report on drug safety. When the US Food and Drug Administration published a preliminary analysis later, it was stated that MSD's oral medication has proven effective in treating COVID-19. However, experts believe that pregnant women are not suitable to take this medication. Experts from the authorities will meet next week to discuss whether to recommend approval for emergency use of the drug.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
